Addition Therapeutics unveiled its PRINT platform for RNA‑mediated insertion of transgenes and disclosed new funding to advance all‑RNA, lipid nanoparticle‑based gene therapies. The company, spun out of UC Berkeley research on retrotransposons, positioned PRINT as a scalable approach to install genes into a single genomic 'safe site' without viral vectors. Addition's public disclosures and fundraise signal investor appetite for alternative gene‑insertion technologies that aim to reduce immunogenicity and manufacturing complexity versus AAV. The startup’s technical claim: RNA plus endogenous transposase machinery can enable persistent expression with potentially lower vector burdens.